Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa

Exclusion Criteria

• •1. A subject with history of epidermoid carcinoma within a year from screening.
• •2. A subject who requires antibiotics due to bacterial infection on skin.
• •3. A subject who was dosed with oral steroid, over 0.5mg/kg a day for subjects under 18, or over 20mg in 2 weeks for subjects over 18, within 30 days prior to screening.
• •4. A subject treated with radiotherapy or immunosuppressants, within 30 days prior to screening.
• •5. A subject treated with steroids locally, within 30 days prior to screening.
• •6. A subject with 2-times the maximum-standardized value of ALT, AST, ALP, bilirubin, total protein
• •7. A subject with 2-times the maximum-standardized value of BUN, Creatinine
• •8. A subject with Albumin below 2.0 g/dL.
• •9. A subject with Hemoglobin below 6 g/dL (anemic).
• •10. A subject with allergic response to bovine derived protein and fibrin glue.
• •11. A subject administered with biologic agents or cell therapy, within 30 days prior to screening.
• •12. A subject administered with stem cell treatment by IV or subcutaneously to the target wound, prior to the trial
• •13. A subject who enrolled into another clinical trial, within 30 days prior to screening
• •14. A subject with serious disease that can affect on clinical trial.
• •15. A pregnant or breast-feeding subject.
• •16. A subject with history of drug abuse within 1 year of clinical significance
• •17. A subject who cannot proceed according to the protocol.